Cencora (COR) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $61.51B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Distribution |
| Country | US | CEO | Robert Mauch |
| IPO Date | 1995-04-04 | CAGR | 14.93% |
| Employees | 49,000 | Website | www.cencora.com |
| Div. Yield | 0.71% | Payout Ratio | 18% |
| Buy Back Yield | 1.53% | Total Yield | 2.24% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $63.35B | P/E | 18.43 | Forward P/E | 16.39 | PEG | 2 |
| P/S | 0.2 | P/B | 19.84 | P/CF | 13.32 | P/FCF | 15.95 |
| Sales | $332.77B | Sales 1Y | 5.09% | Sales 3Y | 30.79% | Sales 5Y | 62.87% |
| EPS | $17.15 | EPS 1Y | 38.52% | EPS 3Y | 63.95% | EPS 5Y | -173.03% |
| Sales QoQ | 8.17% | EPS QoQ | -53.1% | Sales QoQ Avg | 1.45% | EPS QoQ Avg | -68.53% |
| Gross Margin | 3.71% | Operating Margin | 1.3% | Profit Margin | 0.79% | ROCE | 17.62% |
| ROA | 3% | ROE | 104% | Altman Z Score | 4.69 | Piotroski Score | 7 |
| Current Ratio | 0.93 | Quick Ratio | 0.58 | Cash Ratio | 0.05 | Op. CF Ratio | 0.04 |
| Debt/Equity | 3.62 | Debt/Assets | 0.14 | Lt Debt/Equity | 3.53 | Lt Debt/Cap. | 0.78 |
| Intrst Cov. | 8.71 | Inventory Turnover | 15.24 | Asset Turnover | 3.97 | Receivables Turnover | 13.08 |
| Enterprise Value | $63.35B | P/E Ratio | 18.43 |
| Forward P/E | 16.39 | PEG Ratio | 2 |
| P/S Ratio | 0.2 | P/B Ratio | 19.84 |
| P/CF Ratio | 13.32 | P/FCF Ratio | 15.95 |
| EPS | $17.15 | EPS Growth 1Y | 38.52% |
| EPS Growth 3Y | 63.95% | EPS Growth 5Y | -173.03% |
| Revenue Growth 1Y | 5.09% | Gross Margin | 0.04% |
| Operating Margin | 0.01% | Profit Margin | 0.01% |
| ROE | 1.04% | ROA | 0.03% |
| ROCE | 0.18% | Current Ratio | 0.93 |
| Quick Ratio | 0.58 | Cash Ratio | 0.05 |
| Debt/Equity | 3.62 | Interest Coverage | 8.71 |
| Altman Z Score | 4.69 | Piotroski Score | 7 |
Cencora (COR) valuation & financials
Cencora (COR) has a market capitalization of $61.51B and trades at a price-to-earnings ratio of 18.4. It operates in the Healthcare sector (Medical - Distribution).
Cencora's revenue grew +5.1% over the last year.
Cencora's next earnings report is scheduled for November 4, 2026 before market open; analysts estimate EPS of $4.52. Check the earnings calendar to see all companies reporting this week.
Cencora (COR) — frequently asked questions
When does Cencora (COR) report earnings next?
Cencora is expected to report earnings on November 4, 2026 before market open. Analysts estimate EPS of $4.52.
What is Cencora's market cap?
Cencora (COR) has a market capitalization of $61.51B.
What is COR's P/E ratio?
Cencora trades at a price-to-earnings ratio of 18.4, with trailing twelve-month EPS of $17.15.
How fast is Cencora growing?
Cencora's revenue grew +5.1% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)